Skip to main content

IP Update: Jun 18, 2009

Premium

Title: Method for Treating Cancer Using Interference RNA

Number: 20090148535

Filed: Dec. 8, 2008

Inventor: Cynthia Bamdad, Minerva Biotechnologies

The patent application, its abstract states, claims an "acolloidal nanoparticle that includes a therapeutic nucleic acid species [such as an siRNA] and a targeting protein species attached via a coating on the nanoparticle that facilitates the specific attachment of both species."


Title: Application of RNA Interference Targeting DHFR Gene to Cell for Protein Production

Number: 20090148935

Filed: June 5, 2007

Lead Inventor: Suh-Chin Wu, National Tsing Hua University

The patent application, its abstract states, claims biological materials that can be applied to a Chinese hamster ovary cell "or the like for producing a species of protein."

These biological materials include two vectors, the first of which includes mammalian DHFR and protein genes, and the second of which includes "a DNA fragment for inducing … RNA interference in the CHO cell to reduce expression of a DHFR gene of relevance in [the] CHO cell after the second vector is applied to the CHO cell."


Title: Cell Type-Specific Aptamer-siRNA Delivery System for HIV-1 Therapy

Number: 20090148944

Filed: Dec. 5, 2008

Lead Inventor: John Rossi, City of Hope

The invention "relates to compositions and methods for delivery of siRNA to specific cells or tissue," the patent application's abstract states. "More particularly, the … invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer."


Title: Pharmaceutical Composition for Treating Cancer or Diabetes

Number: 20090149402

Filed: Nov. 15, 2005 PCT Filed: Nov. 15, 2005

Lead Inventor: Taeko Miyagi, Miyagi Cancer Center Research Institute

The patent application, its abstract states, claims "a pharmaceutical composition for treating cancer or diabetes [that] contains [a] double-stranded RNA [of a specific sequence listed in the application or] … a double-stranded RNA which has a sequence of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase."

These dsRNAs, the abstract notes, inhibit the expression of a gene encoding human plasma membrane-associated sialidase.


Title: siRNA Silencing of Genes Expressed in Cancer

Number: 20090149403

Filed: May 29, 2007

Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

According to the patent application's abstract, the invention "provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer [such as] Eg5, EGFR, or XIAP, and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR, or XIAP gene expression."


Title: RNA Interference-Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid

Number: 20090149407

Filed: July 9, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention "concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic-discovery applications," the patent application's abstract states. "Specifically, the invention relates to small nucleic acid molecules … capable of mediating RNA interference against beta-secretase, amyloid precursor protein, pin-1, presenillin 1, and/or presenillin 2 gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1, and/or PS-2 expression or activity."


Title: RNA Interference-Mediated Treatment of Telomerase Gene Expression Using Short Interfering Nucleic Acid

Number: 20090149408

Filed: July 9, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating telomerase gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of telomerase gene expression and/or activity by RNA interference using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of telomerase genes, such as telomerase template RNA or a telomerase protein," the abstract adds.


Title: siRNA Targeting KRAS

Number: 20090149644

Filed: Dec. 9, 2008

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.